Skip to main content
. 2020 Feb 21;9(2):496. doi: 10.3390/cells9020496

Figure 6.

Figure 6

eNAMPT antagonizes the CCR5-mediated migration of B16 melanoma cells. (A) CCR5 expression in B16 cells stained with anti-mouse CCR5-PE and analyzed by flow cytometry. (B,C) AUC and percentage of responding cells of B16 cells loaded with FURA-2AM and pretreated with eNAMPT (500 ng/mL; 9 nM) for 100 s before the addition of RANTES (100 ng/mL; 12 nM) at 100 s. Mean ± S.E.M. of 180–210 cells from four independent experiments. (D) Left, representative wound healing images of B16 cells treated with vehicle, Rantes (100 ng/mL; 12 nM), eNAMPT (500 ng/mL; 9 nM) and/or maraviroc (10 µM), and/or CCL7 (250 ng/mL; 22 nM) and CCL3 (100 ng/mL; 9.9 nM) at time 0 and after 24 h of treatment. Right, percentage of wound closure (compared to % of the control) after 24 h of treatment. Mean ± S.E.M. of six determinations from two separate experiments. * p < 0.05, ** p < 0.01, *** p < 0.001.